The FDA’s move will speed up development of MindMed’s LSD-based drug as a treatment for generalized anxiety disorder.
MindMed’s stock soars 58% after FDA grants breakthrough designation to LSD therapy for a form of anxiety
Read Next
- Rep. Ocasio-Cortez fundraising soars as she blasts Trump
- Meta CEO Zuckerberg considered spinning off Instagram 2018: FTC trial
- Trump eyes deporting U.S. citizens to foreign prisons
- Amazon emails sellers to gauge how Trump’s tariffs impacting business
- LSEG appoints Gianluca Biagini and Ron Lefferts as Co-Heads of Global Data & Analytics division
- Blackthorn Finance enters special administration
- What Are the Best Financial Goals for Couples?
